Fate Therapeutics, Inc.
FATE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $6 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $6 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -78.5% | -34% | 72.4% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 100% | -147.4% | 85.7% | 89.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,295.4% | -271.1% | -305.9% | -378.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,366.5% | -253.3% | -292.5% | -379.9% |
| EPS Diluted | -1.64 | -1.64 | -2.91 | -2.24 |
| % Growth | 0% | 43.6% | -29.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |